|
25 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
1 Trial |
|
217 News |
|
| «12345» |
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 11, 2014
P1/2, N=41, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Not yet recruiting --> Recruiting
- Clinical: PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae (clinicaltrials.gov) - May 6, 2014
P=N/A, N=3281, Completed, Sponsor: Centers for Disease Control and Prevention, China
- bortezomib / Generic mfg., irinotecan / Generic mfg.
Enrollment change, Combination therapy, Metastases: Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - May 6, 2014
P2, N=102, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=71 --> 102
- carboplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment closed: CADEN: Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (clinicaltrials.gov) - May 4, 2014
P2, N=25, Active, not recruiting, Sponsor: Baylor College of Medicine
N=71 --> 102 Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Enrollment open: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=50 --> 21
- MK-2206 / Merck (MSD)
Trial completion, Metastases: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 29, 2014
P2, N=21, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 21 Recruiting --> Completed
- Clinical: Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=36, Recruiting, Sponsor: Mayo Clinic
- Avastin (bevacizumab) / Roche
Enrollment change, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=16 --> 11
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
N=16 --> 11 Active, not recruiting --> Completed
- Enrollment change: Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=16, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed N=20 --> 16
- Trial completion: Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=16, Completed, Sponsor: National Taiwan University Hospital
N=20 --> 16 Recruiting --> Completed
- Recentin (cediranib) / AstraZeneca
Enrollment change, Monotherapy, Metastases: Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2014
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=40 --> 19
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=61, Completed, Sponsor: Jiangsu Cancer Institute & Hospital
N=40 --> 19 N=50 --> 61
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Mar 20, 2014
P1/2, N=61, Completed, Sponsor: Jiangsu Cancer Institute & Hospital
N=50 --> 61 Recruiting --> Completed
- | sorafenib / Generic mfg.
Trial completion, Metastases: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=99, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Recruiting --> Completed
- | erlotinib / Generic mfg.
Biomarker, Trial completion, Metastases: Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=58, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | erlotinib / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | erlotinib / Generic mfg.
Trial completion: Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=75, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=55 --> 43
- atorvastatin / Generic mfg.
Enrollment open: Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis (clinicaltrials.gov) - Feb 6, 2014
P2, N=324, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
N=55 --> 43 Active, not recruiting --> Recruiting
- OPB-51602 / Otsuka
Biomarker, New P1 trial, Metastases: OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy (clinicaltrials.gov) - Feb 5, 2014
P1, N=45, Recruiting, Sponsor: National University Hospital, Singapore
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Trial termination, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
Active, not recruiting --> Recruiting Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor.
- Apolactoferrin (talactoferrin alfa) / Agennix, talactoferrin oral (oral rhLF) / Agennix
Enrollment change, Immunomodulating: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Jan 26, 2014
P1, N=4, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Negative data from another trial led to termination of this trial by sponsor. N=20 --> 4
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
New P1/2 trial, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=41, Not yet recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial termination: GORTEC-NPC2006: Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (clinicaltrials.gov) - Jan 1, 2014
P3, N=83, Terminated, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
N=20 --> 4 Recruiting --> Terminated; Low accrual
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment change: GORTEC-NPC2006: Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (clinicaltrials.gov) - Jan 1, 2014
P3, N=83, Terminated, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Recruiting --> Terminated; Low accrual N=260 --> 83
- | atorvastatin / Generic mfg.
New P2 trial: Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis (clinicaltrials.gov) - Dec 25, 2013
P2, N=324, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P3 trial, Metastases: Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC (clinicaltrials.gov) - Dec 12, 2013
P3, N=320, Recruiting, Sponsor: Fudan University
- entolimod (STAT-600) / Coeptis
Trial withdrawal, Metastases: Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Dec 9, 2013
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
N=260 --> 83 Not yet recruiting --> Withdrawn
- entolimod (STAT-600) / Coeptis
Enrollment change, Metastases: Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Dec 9, 2013
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Withdrawn N=36 --> 0
- Avastin (bevacizumab) / Roche
Clinical: Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma (clinicaltrials.gov) - Dec 8, 2013
P2, N=43, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
N=36 --> 0 N=60 --> 43
- Avastin (bevacizumab) / Roche
Clinical: Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma (clinicaltrials.gov) - Dec 8, 2013
P2, N=43, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
N=60 --> 43 Recruiting --> Completed
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Dec 7, 2013
P2, N=54, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Dec 3, 2013
P2, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=43 --> 22
- MK-2206 / Merck (MSD)
Enrollment closed, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Nov 11, 2013
P2, N=45, Active, not recruiting, Sponsor: Chinese University of Hong Kong
N=43 --> 22 Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China (clinicaltrials.gov) - Oct 28, 2013
P2, N=60, Completed, Sponsor: Fourth Military Medical University
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Aqupla (nedaplatin) / Simcere
Enrollment change, Head-to-Head, Metastases: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 1, 2013
P3, N=372, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Completed N=256 --> 372
- saracatinib (AZD0530) / AstraZeneca
Enrollment change, Metastases: Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Aug 12, 2013
P2, N=9, Completed, Sponsor: National Cancer Institute (NCI)
N=256 --> 372 N=28 --> 9
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: REPLACE: Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 9, 2013
P2, N=60, Completed, Sponsor: Sun Yat-sen University
N=28 --> 9 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Sutent (sunitinib) / Pfizer
Trial termination, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Terminated
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Sutent (sunitinib) / Pfizer
Trial initiation date, Metastases: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 30, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Initiation date: Jul 2007 --> Jul 2008
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2007 --> Jul 2008 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Trial initiation date, Metastases: Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer (clinicaltrials.gov) - Jun 27, 2013
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Jun 2006 --> Aug 2007
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment change, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Jun 13, 2013
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Jun 2006 --> Aug 2007 N=80 --> 18